Navigation Links
Misonix Reports a 29% and 24% Increase in Revenue for the Second Quarter and Six Months Fiscal 2012 Financial Results
Date:2/8/2012

FARMINGDALE, N.Y., Feb. 8, 2012 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures, and markets innovative therapeutic ultrasonic products worldwide for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical and medical applications, today reported financial results for the second fiscal quarter and six months ending December 31, 2011.  Michael A. McManus Jr., President and Chief Executive Officer, and Richard Zaremba, Senior Vice President and Chief Financial Officer, will host a conference call Wednesday, February 8, 2012 at 4:30 pm EASTERN to discuss the Company's second quarter results.

The Company also reported the following financial and operational achievements:

  • A 29% increase in revenue for the three months ending December 31, 2011 compared with the same period ending December 31, 2010.
  • A 24% increase in revenue for the six months ending December 31, 2011 compared with the same period ending December 31, 2010.
  • Gross profits as a percentage of revenue were 63.9% for the three months ending December 31, 2011 compared with 62.4% for the three months ending December 31, 2010.
  • Gross profits as a percentage of revenue were 59.6% for the six months ending December 31, 2011 compared with 58.6% for the six months ending December 31, 2010.
  • Net income reported from continuing operations of $228,000 for the three months ending December 31, 2011 compared with a loss of $505,000 for the same period in fiscal 2011.
  • Sold Laboratory and Forensic Safety Products business for $1.5 million plus potential $500,000 over the next 3 years.

  • Revenue for the three months ended December 31, 2011 was $3.6 million, a 29% increase when compared with $2.8 million for the same period in fiscal 2011.  The increase in medical device products sales was primarily attributable to sales of the Company's BoneScalpel™ and Neuroaspirator products.

    Gross profit as a percentage of sales (gross profit percentage) was 63.9% for the three months ended December 31, 2011 compared with 62.4% for the three months ended December 31, 2010.  

    The Company reported income from continuing operations of $228,000 or $0.03 per diluted share for the three months ended December 31, 2011 compared with a loss of $505,000 or $(0.07) loss for the same period in fiscal 2011.  The Company reported net income for the three months ended December 31, 2011 of $1.0 million, or $0.15 per share, compared to a net loss of $536,000, or $(0.08) per share, for the three months ended December 31, 2010.

    Revenue for the six months ended December 31, 2011 was $6.8 million, a 24% increase when compared with $5.5 million for the same period in fiscal 2011.

    The Company reported net income of $136,000 or $0.02 per share for the six months ended  December 31, 2011 compared with a net loss of $1.6 million or $(0.22) per share for the six months ended December 31, 2010.

    Commenting on Misonix's financial and operating results, Michael A. McManus Jr., President and Chief Executive Officer, said, "We are pleased at the growth of our revenues and continued trends in gross margins particularly with respect to our core medical device products. We continue to reduce G&A expenses, having made additional progress this quarter. We will continue to manage our administrative expenses prudently, while supporting investments in product development and sales and marketing.  In late October, we announced the sale of our Laboratory and Forensic Safety Products business.  This sale of a non-core business completes our strategy to focus exclusively on medical device products and enabled us to strengthen our balance sheet with an additional $1.5 million and an opportunity to receive an additional $500,000 in total over the next three years.  Our plan is to use the proceeds to continue to invest in sales and marketing efforts in our medical device business.  

    "We remain committed to our strategic vision and belief that increased medical device sales through our proprietary sales channels, our emphasis on high margin disposables, a broader geographic reach and development of new surgical applications and technology will strengthen and grow the Company over time."

    Conference Call:Misonix management will host a conference call and webcast on Wednesday, February 8, 2012 at 4:30 pm EASTERN to discuss second quarter results.

    Shareholders and other interested parties may participate in the conference call by dialing 877-317-6789 (domestic) or 412-317-6789 (international), a few minutes before the start of the call. A simultaneous webcast will be available via Misonix's website at www.misonix.com. The call will be archived on the Company's website for at least 90 days.

    A recording of the live-call will be available for three days at 877-344-7529 or 412-317-0088, confirmation #10009914.

    About Misonix:Misonix, Inc. designs, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

    With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.Misonix Contact:

    Investor Relations Contact:Richard Zaremba

    Joe Diaz, Lytham Partners631-694-9555

    602-889-9700invest@misonix.com

    diaz@lythampartners.comMISONIX, INC. And SubsidiariesConsolidated Balance SheetsDecember 31, 2011June 30, 2011UnauditedDerived from auditedfinancial statementsAssetsCurrent Assets:   Cash and cash equivalents$6,696,617$6,881,093   Accounts receivable, less allowancefor doubtful accounts of $140,739 and$115,739, respectively1,875,9842,085,972   Inventories, net3,658,4093,130,207   Prepaid expenses and other current assets172,224374,472   Note receivable410,500210,000   Current assets of discontinued operations498,234857,095Total current assets13,311,96813,538,839Property, plant and equipment, net958,664969,336Goodwill1,701,0941,701,094Other assets1,748,3382,127,194Assets of discontinued operations-21,859Total assets$17,720,064$18,358,322Liabilities and stockholders' equityCurrent liabilities:   Accounts payable$
    ,041,124$
    ,110,694   Accrued expenses and other current liabilities1,109,4551,969,078   Liabilities of discontinued operations228,675225,864Total current liabilities2,379,2543,305,636Deferred income$
    39,253$
    ,360Deferred lease liability18,51914,043Total liabilities2,537,0263,481,039Commitments and contingenciesStockholders' equity:   Capital stock, $0.01 par value - shares authorized 20,000,000; 7,079,170   issued and 7,001,370 outstanding, respectively70,79270,792   Additional paid-in capital25,957,57825,787,960   Accumulated deficit(10,432,908)(10,569,045)   Treasury stock, 77,800 shares(412,424)(412,424)Stockholders' equity15,183,03814,877,283Total liabilities and stockholders' equity$17,720,064$18,358,322MISONIX, INC. And SubsidiariesConsolidated Statements of OperationsUnauditedThree Months EndedSix Months EndedDecember 31,December 31,2011

    20102011

    2010Net sales

    $3,550,535

    $2,762,556$6,767,734

    $5,454,824Cost of goods sold

    1,281,561

    1,039,3072,734,968

    2,259,004Gross profit

    2,268,974

    1,723,2494,032,766

    3,195,820Selling expenses

    1,194,045

    907,6932,374,297

    1,728,207General and administrative expenses

    1,082,385

    1,109,4822,250,205

    2,327,287Research and development expenses

    303,702

    352,161613,676

    733,438Total operating expenses

    2,580,132

    2,369,3365,238,178

    4,788,932Loss from operations

    (311,158)

    (646,087)(1,205,412)

    (1,593,112)Total other income

    331,871

    144,682427,099

    346,272Income (loss) from continuing operations before  income taxes

    20,713

    (501,405)(778,313)

    (1,246,840)Income tax (benefit) expense

    (207,233)

    4,000(202,273)

    42,100Net income (loss) from continuing operations

    227,946

    (505,405)(576,040)

    (1,288,940)Discontinued operations:Net loss from discontinued operations, net of tax benefit of $130,517,$0,$130,517 and $0, respectively

    (126,225)

    (30,761)(206,181)

    (265,072)Net gain from sale of discontinued operations net of tax expense of $532,268,$0,$532,268 and $0, respectively

    918,358

    -918,358

    -Net income (loss) from discontinued operations

    792,133

    (30,761)712,177

    (265,072)Net income (loss)

    $1,020,079

    ($536,166)$136,137

    ($1,554,012)Net income (loss) per share from continuing operations-Basic

    $0.03

    ($0.07)($0.08)

    ($0.18)Net income (loss) per share from discontinued operations-Basic

    0.11

    (0.01)0.10

    (0.04)Net income (loss) per share-Basic

    $0.15

    ($0.08)$0.02

    ($0.22)Net income (loss) per share from continuing operations-Diluted

    $0.03

    ($0.07)($0.08)

    ($0.18)Net income (loss) per share from discontinued operations-Diluted

    0.11

    (0.01)0.10

    (0.04)Net income (loss) per share-Diluted

    $0.15

    ($0.08)$0.02

    ($0.22)Weighted average common shares-basic

    7,001,370

    7,001,3707,001,370

    7,001,370Weighted average common shares-diluted

    7,001,370

    7,001,3707,001,370

    7,001,370
    '/>"/>

    SOURCE Misonix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
    2. Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results
    3. Misonix, Inc. Announces the Sale of Sonora Medical Systems for $8 Million
    4. Misonix Announces New Distribution Agreement for United Kingdom and Republic of Ireland
    5. Misonix Announces New Distribution Agreement for Mexico
    6. Misonix Schedules First Quarter 2010 Financial Results Conference Call; November 16, 2009 at 4:30 p.m. Eastern
    7. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
    8. Misonix Announces New Distribution Agreement for Peru
    9. Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE)
    10. Misonix Announces New Distribution Agreement for Argentina
    11. Misonix Announces New Distribution Agreement for Kingdom of Saudi Arabia
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/8/2016)... -- http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced ... Equipment Market 2016-2020" report to their offering. ... announced the addition of the "Global Skin ... offering. --> Research and ... of the "Global Skin Protective Equipment Market ...
    (Date:2/8/2016)... 8, 2016 In a historic vote among its members this ... a medical cannabis cultivation facility and dispensary on tribal land near ... as a provider for patients in the state,s Medical Cannabis ... as a provider for patients in the state,s Medical Cannabis Program. ... approve the project and pursue designation from the State of ...
    (Date:2/8/2016)... 2016  A research team led by St. ... of how the abnormal breakage and rearrangement of chromosomes ... of acute lymphoblastic leukemia (ALL). Such leukemias are cancers ... overproduction of immature cells, called lymphoblasts. ... malfunction underlying the type called "Ph-like ALL" will aid ...
    Breaking Medicine Technology:
    (Date:2/8/2016)... ... ... who has struggled to quit smoking, a man who has struggled with hair loss – ... his problems – and he did. Now Nabat, a serial entrepreneur featured as the October ... to the world and better people's lives. His own experience with nicotine addiction led to ...
    (Date:2/8/2016)... ... 2016 , ... Tingley Rubber Corporation , a leading ... range of unique and advantaged protective solutions to a growing and dynamic ... customer service and marketing support. A new distribution center in Brampton, Ontario will ...
    (Date:2/8/2016)... , ... February 08, 2016 , ... ... enrichment program serving the greater Venice, FL area, has initiated a fundraiser for ... a car accident just four days after Christmas. To support this beautiful child ...
    (Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should try ... Clay” the health benefits of integrating clay into a daily diet are numerous, as ... motivational speaker, Perry A~ has since dedicated her life to learning about the benefits ...
    (Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s ... booths and 700 companies. Attendees also get to see the most incredible gardens ... & Home Show , at the Colorado Convention Center - 700 14th St. Denver ...
    Breaking Medicine News(10 mins):